Product Description
an orally active protease-activated receptor-1 antagonist that has recently completed Phase II clinical investigation. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22871190/)
Mechanisms of Action: PAR1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Coronary Syndrome|Coronary Artery Disease|Myocardial Ischemia|Inflammation|Coronary Disease
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| E5555-A001-023 | P1 |
Completed |
Healthy Volunteers |
2011-08-01 |
2019-03-19 |
Treatments |
|
| E5555-A001-022 | P1 |
Completed |
Healthy Volunteers |
2010-12-01 |
2019-03-19 |
Treatments |
|
| E5555-J081-207 | P2 |
Completed |
Acute Coronary Syndrome |
2009-09-01 |
2019-03-18 |
Treatments |
|
| LANCELOT ACS (Acute Coronary Syndrome) | P2 |
Completed |
Acute Coronary Syndrome|Coronary Disease |
2009-08-30 |
2025-06-02 |
Treatments |
|
| 2006-000296-15 | P2 |
Completed |
Coronary Artery Disease |
2009-06-09 |
2022-03-12 |
Treatments |
|
| E5555-G000-201 | P2 |
Completed |
Coronary Artery Disease |
2009-04-02 |
2022-03-12 |
Treatments |
|
| E5555-G000-202 | P2 |
Completed |
Acute Coronary Syndrome |
2009-04-01 |
2019-03-22 |
Treatments |
|
| JapicCTI-080560 | P2 |
Completed |
Coronary Artery Disease |
2009-03-30 |
|||
| E5555-J081-206 | P2 |
Completed |
Myocardial Ischemia|Coronary Artery Disease |
2009-03-01 |
2019-03-21 |
||
| JapicCTI-070496 | P2 |
Completed |
Acute Coronary Syndrome |
2008-09-08 |
|||
| E5555-G000-201 | P2 |
Completed |
Coronary Artery Disease|Myocardial Ischemia|Inflammation |
2008-03-01 |
2019-03-21 |
Treatments |
|
| LANCELOT CAD | P2 |
Recruiting |
Coronary Artery Disease |
None |
2024-04-03 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/16/2024 |
PubMed |
Therapeutic Effect of Proteinase-Activated Receptor-1 Antagonist on Colitis-Associated Carcinogenesis. |
|
01/25/2024 |
PubMed |
Depression, Anxiety, Body Dissatisfaction, and Eating Disorders in Plastic Surgery Patients. |
|
12/09/2022 |
PubMed |
Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs. |